Clinical trial
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer: A Community-Based Randomized Controlled Trial
NCT06306755 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer: A Community-Based Randomized Controlled Trial
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- June 25, 2024
- Completion date
- December 31, 2034
- Enrollment
- 21,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
esophageal cancer, gastric cancer, precision screening, risk stratification, sequential screening